drugset / Trial / NCT04975438
Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate efficacy and safety of GSK1070806 in moderate to severe atopic dermatitis (AtD) participants.
Timeline
- Start
- 2021-11-18
- Primary completion
- 2022-12-19
- Completion
- 2023-03-13
Outcome
Met primary endpoint
registry Posterior Median Difference -33.21 (95% CI -50.96 to -14.84) NCT04975438 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK1070806 | Monoclonal antibody | 2 mg/kg | Intravenous |